Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation
Adrian Achuthan, … , Stephen J. Turner, John A. Hamilton
Adrian Achuthan, … , Stephen J. Turner, John A. Hamilton
Published August 15, 2016
Citation Information: J Clin Invest. 2016;126(9):3453-3466. https://doi.org/10.1172/JCI87828.
View: Text | PDF
Research Article Inflammation Article has an altmetric score of 3

Granulocyte macrophage colony-stimulating factor induces CCL17 production via IRF4 to mediate inflammation

  • Text
  • PDF
Abstract

Data from preclinical and clinical studies have demonstrated that granulocyte macrophage colony-stimulating factor (GM-CSF) can function as a key proinflammatory cytokine. However, therapies that directly target GM-CSF function could lead to undesirable side effects, creating a need to delineate downstream pathways and mediators. In this work, we provide evidence that GM-CSF drives CCL17 production by acting through an IFN regulatory factor 4–dependent (IRF4-dependent) pathway in human monocytes, murine macrophages, and mice in vivo. In murine models of arthritis and pain, IRF4 regulated the formation of CCL17, which mediated the proinflammatory and algesic actions of GM-CSF. Mechanistically, GM-CSF upregulated IRF4 expression by enhancing JMJD3 demethylase activity. We also determined that CCL17 has chemokine-independent functions in inflammatory arthritis and pain. These findings indicate that GM-CSF can mediate inflammation and pain by regulating IRF4-induced CCL17 production, providing insights into a pathway with potential therapeutic avenues for the treatment of inflammatory diseases and their associated pain.

Authors

Adrian Achuthan, Andrew D. Cook, Ming-Chin Lee, Reem Saleh, Hsu-Wei Khiew, Melody W.N. Chang, Cynthia Louis, Andrew J. Fleetwood, Derek C. Lacey, Anne D. Christensen, Ashlee T. Frye, Pui Yeng Lam, Hitoshi Kusano, Koji Nomura, Nancy Steiner, Irmgard Förster, Stephen L. Nutt, Moshe Olshansky, Stephen J. Turner, John A. Hamilton

×

Figure 7

GM-CSF–induced CCL17 expression in monocytes/macrophages is IRF4 dependent.

Options: View larger image (or click on image) Download as PowerPoint
GM-CSF–induced CCL17 expression in monocytes/macrophages is IRF4 depende...
(A and B) Human monocytes were treated with either PBS or GM-CSF (10 ng/ml) for 16 hours. (A) IRF4 and IRF5 mRNA expression (qPCR) and (B) whole cell lysates were subjected to Western blotting with anti-IRF4, anti-IRF5, and anti–β-actin antibodies (n = 4). (C and D) Human monocytes were nucleofected with IRF4, IRF5, or a control nontargeting (CNT) siRNA before being stimulated with GM-CSF (10 ng/ml) for 16 hours. (C) IRF and cytokine/chemokine mRNA expression plotted relative to that in CNT siRNA, which was given an arbitrary value of 1.0, and (D) secreted CCL17 by ELISA (n = 5). (E and F) Murine bone marrow cells were cultured in M-CSF (5,000 U/ml) for 7 days to derive BMM followed by GM-CSF treatment in the absence of M-CSF. (E) Irf4 mRNA expression (24 hours) and (F) whole cell lysates from BMM treated with GM-CSF for the indicated periods of time were subjected to Western blotting with anti-IRF4 and anti–β-actin antibodies (n = 4). (G) Representative histograms of IRF4 in CCL17/EGFP+ and CCL17/EGFP– populations of BMM (from Ccl17E/+ mice) treated with fresh medium containing either M-CSF or GM-CSF for 72 hours (n = 3). (H and I) BMM from WT or Irf4–/– mice were stimulated with GM-CSF (10 ng/ml) for 24 hours in the absence of M-CSF. (H) Cytokine mRNA expression and (I) secreted CCL17 protein in the supernatant (ELISA) (n = 4). (J and K) Thioglycolate-elicited peritoneal macrophages were treated with PBS (vehicle) and GM-CSF (20 ng/ml) for 24 hours. (J) Irf4 mRNA expression in WT macrophages and (K) cytokine mRNA expression in WT and Irf4–/– macrophages (n = 4). Graphs are plotted as mean ± SEM. P values were obtained using a t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 5 X users
127 readers on Mendeley
See more details